PURPOSE: Leading professional organizations acknowledge the importance of an informed decision-making process for prostate cancer screening.
We describe primary care physicians' reports of their prescreening discussions about the potential harms and benefits of prostate cancer screening.
METHODS: Members of the American Academy of Family Physicians National Research Network responded to a survey that included (1) an indicator of practice styles related to discussing harms and benefits of prostate-specific antigen testing and providing a screening recommendation or letting patients decide, and (2) indicators reflecting physicians' beliefs about prostate cancer screening. The survey was conducted between July 2007 and January 2008.
RESULTS: Of 426 physicians 246 (57.7%) completed the survey questionnaire. Compared with physicians who ordered screening without discussion (24.3%), physicians who discussed harms and benefits with patients and then let them decide (47.7%) were more likely to endorse beliefs that scientific evidence does not support screening, that patients should be told about the lack of evidence, and that patients have a right to know the limitations of screening; they were also less likely to endorse the belief that there was no need to educate patients because they wanted to be screened. Concerns about medicolegal risk associated with not screening were more common among physicians who discussed the harms and benefits and recommended screening than among physicians who discussed screening and let their patients decide.
CONCLUSIONS: Much of the variability in physicians' use of an informed decision-making process can be attributed to beliefs about screening. Concerns about medicolegal risk remain an important barrier for shared decision making.
Written by:
Volk RJ, Linder SK, Kallen MA, Galliher JM, Spano MS, Mullen PD, Spann SJ. Are you the author?
Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Reference: Ann Fam Med. 2013 Jan;11(1):67-74.
doi: 10.1370/afm.1445
PubMed Abstract
PMID: 23319508
UroToday.com Prostate Cancer Section
